Lipid metabolism reprogramming in cardiac fibrosis

Trends Endocrinol Metab. 2023 Nov 8:S1043-2760(23)00217-5. doi: 10.1016/j.tem.2023.10.004. Online ahead of print.ABSTRACTCardiac fibrosis is a critical pathophysiological process that occurs with diverse types of cardiac injury. Lipids are the most important bioenergy substrates for maintaining optimal heart performance and act as second messengers to transduce signals within cardiac cells. However, lipid metabolism reprogramming is a double-edged sword in the regulation of cardiomyocyte homeostasis and heart function. Moreover, lipids can exert diverse effects on cardiac fibrosis through different signaling pathways. In this review, we provide a brief overview of aberrant cardiac lipid metabolism and recent progress in pharmacological research targeting lipid metabolism alterations in cardiac fibrosis.PMID:37949734 | DOI:10.1016/j.tem.2023.10.004
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Source Type: research